Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Clinical trial NCT05243797 · RECRUITING
Trial details
- NCT number
- NCT05243797
- Sponsor
- European Myeloma Network B.V.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-08
- Primary completion
- 2028-04-01
- Enrollment
- 1594
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.